StarMab BioMed

StarMab BioMed, founded in 2019, has developed the world’s first VHH antibody discovery and engineering optimization platform, which ensures efficient selection and optimization of VHH antibodies, generating VHH antibody candidates with high affinity and high bioactivity. The platform overcomes challenges related to stability, immunogenicity, half-life, and manufacturability. Its unique nano-polyantibody molecules exhibit high-affinity targeting and synergistic effects, adjustable half-life, mediation of ADCC and ADCP, simple structure, small molecular weight, high expression levels, high purification recovery rates, and excellent stability. Relying on its proprietary technology platform, StarMab BioMed has developed a series of novel biologics with independent intellectual property rights. Among them, SM3321 is about to initiate clinical filings in both China and the United States. Preclinical data have demonstrated excellent anti-tumor efficacy and safety: the unique binding site enables strong targeting of tumor cells, activation of immune cell functions, and reduction of non-specific toxic reactions.